At Mirimus, we bridge the gap between research innovation and clinical success. Our preclinical drug discovery services deliver the testing, validation, and insights needed to advance your therapeutic candidates faster and with confidence. From small molecules to gene and RNAi-based therapies, our expert team provides precise, reproducible studies that evaluate efficacy, safety, and mechanism of action.
.png)
In Vitro Screening for Efficacy & Potency
Mechanistic & Target Engagement Studies
In Vivo Efficacy & Safety Assessment
PK/PD Profiling
Functional Activity Assays for Efficacy
In Vitro & In Vivo Binding and Affinity Testing
PK/PD Profiling
Safety Assessment & Toxicity Studies
Custom Design, Synthesis, and Validation of siRNA, shRNA, and artificial miRNA Triggers
Target Gene Assessment
Development of LNPs & Viral Delivery Systems
In Vitro & In Vivo Testing for Efficacy & Safety
Design & Validation of CRISPR Guide RNAs
Targeted Gene Knock-out/Knock-in
CRISPR Screening for Functional Studies & Target Discovery
Functional Assays to Confirm Editing Efficacy
Development of Stable & Bioavailable Formulations
LNP & Viral Vector Formulations for RNAi Delivery
Formulations for Various Routes of Administration (Oral, Injectable, Topical)
Bioavailability & PK Profiling for Improved Delivery
In Vitro Cytotoxicity & Genotoxicity Testing
In Vivo Acute & Chronic Toxicity Studies
Dose-Response Analysis & Toxicokinetic Profiling
Safety Pharmacology & Biomarker Identification
ADME Studies for Pharmacokinetic Profiling
In Vivo PK/PD Modeling for Dose Selection
Exposure-Response Relationships
Mechanistic Studies to Support Therapeutic Efficacy
Engineered microRNA scaffolds for potent gene silencing in vivo (Militello et al., 2025, Scientific Reports)
HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells (Krzesaj et al., 2025, Ann Clin Lab Sci)
Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma (Robert et al., 2014, Proc Natl Acad Sci USA)
With a focus on both in-house development and client-provided compound testing, Mirimus offers a complete range of preclinical drug discovery services. Our expertise ensures that your small molecules, biologics, RNAi therapeutics, and CRISPR candidates are fully characterized, optimized, and ready for clinical advancement. Contact us today to learn how we can accelerate your drug discovery journey.
Contact Us
.png)
.png)
.png)
